SEC Tracker
Get the app

Ani Pharmaceuticals ANIP

Ani Pharmaceuticals Q2 FY25: revenue $211.4M, up 53%; diluted EPS $0.36

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Ani Pharmaceuticals reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$211.4M+53% from $138.0M in Q2 FY2410-Q income statement, on EDGAR
  2. Net income$8.5MAgainst −$2.3M in Q2 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.36Against −$0.14 in Q2 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$217.8M−9% from $240.1M in Q2 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations$75.8M+335% from $17.4M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Ani Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025
  2. Travere Therapeutics TVTX public float $1.3B, Jun 30, 2025
  3. Innoviva INVA public float $1.3B, Jun 30, 2025
  4. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025
  5. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.